How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about axicabtagene ciloleucel

    Anticipated marketing authorisation indication

    2.1 Axicabtagene ciloleucel (Yescarta, Kite) is indicated 'for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy'. Axicabtagene ciloleucel has not yet been granted a marketing authorisation from the Medicines and Heathcare products Regulatory Agency (MHRA). On 22 April 2022 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for axicabtagene ciloleucel, intended for treating relapsed or refractory follicular lymphoma after 3 or more lines of systemic therapy.

    Dosage in the marketing authorisation

    2.2 The dosage schedule will be available in the summary of product characteristics for axicabtagene ciloleucel.

    Price

    2.3 The list price for axicabtagene ciloleucel is £280,451. The company has a commercial arrangement. This makes axicabtagene ciloleucel available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.